TRX-COBI

• UNSPSC Description:

  TRX-COBI ((R,R)-TRX-COBI; Trx-cobimetinib) is a MEK inhibitor targeting TRX fragments based on Fe2+. TRX-COBI has antitumor activity[1].

• Target Antigen:

  MEK

• Type:

  Reference compound

• Related Pathways:

  MAPK/ERK Pathway

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/trx-cobi.html

• Solubility:

  10 mM in DMSO

• Smiles:

  FC(C=C(C=C1)I)=C1NC(C(F)=C(C=C2)F)=C2C(N3CC([C@H]4N(C(O[C@H]5C[C@]6(OOC7([C@@H](C8)C[C@H]9C[C@@H]8C[C@@H]7C9)O6)CCC5)=O)CCCC4)(O)C3)=O

• Molecular Weight:

  837.66

• References & Citations:

  [1]Jiang H, et al. Ferrous iron-activatable drug conjugate achieves potent MAPK blockade in KRAS-driven tumors. J Exp Med. 2022 Apr 4;219(4):e20210739.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported